{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Response and progression will be evaluated in this study using the international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in RECIST. The response assessment is based on the presence, absence, or unequivocal progression of the lesions.","groups":[{"description":"Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment\n\nGC1008: GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.","id":"OG000","title":"Investigational Drug infusion-for Safety and Effectiveness"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Outcome analysis presented in manuscript of results of trial based on 13 participants.","reportingStatus":"POSTED","timeFrame":"18 months","title":"Response Rate Using Modified RECIST Criteria for Mesothelioma","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}